Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDHA, BIK, and CNIH4 Are Diagnostic Markers of Endoplasmic Reticulum Stress in Lung Cancer Comorbid With Sepsis: Integrating Machine Learning and Single-Cell Analysis of Immune Signaling.

Mediators of inflammation·2026
Same author

Identification of ZNF469 as a potential biomarker and therapeutic target for gastric cancer through integrated multi dataset analysis.

Discover oncology·2026
Same author

Interventional Potential of Panax Genus Chinese Medicinals in Atherosclerosis Progression.

Phytotherapy research : PTR·2026
Same author

Preoperative electrolyte-based metabolic biomarkers for prognostic assessment in gastric cancer: a multicenter study.

Frontiers in endocrinology·2026
Same author

Network-informed multi-trait genomic analysis decodes the shared genetic architecture and therapeutic landscape of pelvic floor disorders.

npj aging·2026
Same author

Tapioca starch-yeast protein 3D printing system for dysphagia: Different hydrocolloids regulate viscoelasticity and 3D printing accuracy through molecular interactions.

Food chemistry·2026

Related Experiment Video

Updated: Jun 18, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Challenges and recent advances in CAR-T cell therapy for solid tumors.

Zhixun Guo1, Dewen Zhong2, Dongxue Jiao3

  • 1Shengli Clinical Medical College of Fujian Medical University, Department of Urology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, PR China.

Critical Reviews in Oncology/Hematology
|June 16, 2026
PubMed
Summary
This summary is machine-generated.

Chimeric Antigen Receptor T-cell (CAR-T) therapy shows promise for solid tumors but faces challenges. Breakthrough strategies and novel targets are being explored to overcome these obstacles for better cancer treatment.

Keywords:
CAR engineeringCAR-T cell therapySolid tumorsTumor microenvironment remodeling

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jun 18, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized hematological cancer treatment.
  • Significant hurdles impede the application of CAR-T therapy in solid tumors.

Purpose of the Study:

  • This review consolidates current challenges and recent breakthrough strategies for CAR-T therapy in solid tumors.
  • It aims to provide insights for advancing CAR-T research and clinical translation.

Main Methods:

  • The review synthesizes information on obstacles like tumor antigen heterogeneity, immunosuppressive tumor microenvironment (TME), T-cell infiltration issues, and toxicities.
  • It highlights innovative approaches including novel target discovery, advanced CAR designs, local delivery methods, and combination therapies.

Main Results:

  • Novel targets such as Claudin 18.2 and B7-H3 are being investigated.
  • Innovative CAR designs (logic-gated, armored CARs) and combination strategies (radiotherapy, checkpoint inhibitors, oncolytic viruses) show potential.
  • Local delivery and in situ generation techniques are emerging solutions.

Conclusions:

  • Overcoming solid tumor challenges requires innovative CAR-T strategies, novel targets, and advanced delivery systems.
  • Multidisciplinary integration is crucial for developing intelligent, controllable next-generation CAR-T technologies for improved clinical outcomes.